Results 251 to 260 of about 29,210 (297)

CAR T-cells and Time-Limited Ibrutinib as Treatment for Relapsed/Refractory Mantle Cell Lymphoma: Phase II TARMAC Study.

Blood, 2023
CD19-directed chimeric antigen receptor T-cells achieve high response rates in patients with relapsed or refractory mantle cell lymphoma. However, their use is associated with significant toxicity, relapse is a concern, and their broad tractability is ...
A. Minson, N. Hamad, C. Cheah, Constantine S Tam, P. Blombery, David A. Westerman, David Ritchie, Huw Morgan, N. Holzwart, S. Lade, M. Anderson, A. Khot, J. F. Seymour, M. Robertson, Imogen Caldwell, G. Ryland, J. Saghebi, Zahra Sabahi, Jing Xie, R. Koldej, M. Dickinson   +20 more
semanticscholar   +1 more source

Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities.

NEJM Evidence, 2022
Fixed-Duration Ibrutinib-Venetoclax for CLLAmong 211 patients with CLL who received ibrutinib-venetoclax or chlorambucil-obinutuzumab, there were 22 and 67 progression-free survival (PFS) events at a median follow-up of 27.7 months, respectively. PFS was
A. Kater, C. Owen, C. Moreno, G. Follows, T. Munir, M. Levin, O. Benjamini, A. Janssens, A. Osterborg, T. Robak, M. Šimkovič, D. Stevens, S. Voloshin, V. Vorobyev, L. Ysebaert, R. Qin, A. Steele, N. Schuier, K. Baeten, D. B. Caces, C. Niemann   +20 more
semanticscholar   +1 more source

Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

American Journal of Hematology, 2019
Ibrutinib, a once‐daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Talha Munir, Jennifer R Brown, Susan M O'brien   +2 more
exaly   +2 more sources

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

Leukemia, 2019
RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years ( n  = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or ...
Jan A Burger, Paul M Barr, Tadeusz Robak
exaly   +2 more sources

EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B cell lymphoma.

Blood, 2023
The use of Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib to block B cell receptor (BCR) signaling has achieved a remarkable clinical response in several B cell malignancies including mantle cell lymphoma (MCL) and diffuse large B cell ...
Yunxia Liu, Shuichi Kimpara, N. Hoang, Anusara Daenthanasanmak, Yangguang Li, Li Lu, Vu N. Ngo, P. Bates, Longzhen Song, Xiaoyue Gao, S. Bebel, Madelyn Chen, Ruoyu Chen, Xiyu Zhang, Paul E. Selberg, V. Kenkre, C. Capitini, Thomas Waldmann, L. Rui   +18 more
semanticscholar   +1 more source

Ibrutinib (Imbruvica)

Canadian Journal of Health Technologies, 2023
CADTH recommends that ibrutinib, in combination with venetoclax, should be reimbursed by public drug plans for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL), including those with 17p deletion only if certain conditions are met. In combination with venetoclax, Ibrutinib should only be covered ...
openaire   +1 more source

Ibrutinib

2018
Abnormal B-cell receptor (BCR) signalling is a key mechanism of disease progression in B-cell malignancy. Bruton's tyrosine kinase (BTK) has a pivotal role in BCR signalling. Ibrutinib (PCI-32765) is a small molecule which serves as a covalent irreversible inhibitor of BTK. It is characterized by high selectivity for BTK and high potency.
Andriani, Charalambous, Mark-Alexander, Schwarzbich, Mathias, Witzens-Harig   +2 more
openaire   +2 more sources

Ibrutinib

2014
Abnormal B-cell receptor (BCR) signaling is a key mechanism of disease progression in B-cell malignancy. Bruton's tyrosine kinase (BTK) has a pivotal role in BCR signaling. Ibrutinib (PCI-32765) is a novel agent which serves as a covalent irreversible inhibitor of BTK. It is characterized by high selectivity for BTK and high potency.
Mark-Alexander, Schwarzbich, Matthias, Witzens-Harig   +1 more
openaire   +2 more sources

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

Nature Medicine, 2015
Ryan M Young, Stefania Pittaluga, George W Wright   +2 more
exaly   +2 more sources

Long-term Follow-up from A041202 Shows Continued Efficacy of Ibrutinib Regimens for Older Adults with CLL.

Blood
A041202 (NCT01886872) is a phase 3 study comparing bendamustine plus rituximab (BR) with ibrutinib and the combination of ibrutinib plus rituximab (IR) in previously untreated older patients with CLL.
J. Woyach, Gabriela E Perez Burbano, A. Ruppert, Cecelia R Miller, N. Heerema, Weiqiang Zhao, A. Wall, Wei Ding, Nancy L. Bartlett, D. Brander, P. Barr, K. Rogers, S. Parikh, Deborah M. Stephens, Jennifer R. Brown, G. Lozanski, J. Blachly, S. Nattam, Richard A. Larson, H. Erba, M. Litzow, S. Luger, Carolyn Owen, C. Kuzma, J. Abramson, Richard F. Little, S. Dinner, Richard M. Stone, G. Uy, Wendy Stock, S. Mandrekar, John C Byrd   +31 more
semanticscholar   +1 more source